Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0771 • ACR Convergence 2024
Arid5b Controls Pathologic Inflammatory versus Invasive Fibroblast Behavior
Angela Zou¹, Suppawat Kongthong², Cassandra Murphy², Gerald Watts³, Alisa Mueller⁴ and Michael Brenner⁵, ¹Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Brookline, MA, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital, Harvard Medical School, Newton, MA
Background/Purpose: Synovial fibroblasts assume both inflammatory and tissue invasive roles in rheumatoid arthritis (RA). Recent studies have shown that these inflammatory and invasive functions are…
Abstract Number: 0872 • ACR Convergence 2024
Investigating the Natural Improvement of Rheumatoid Arthritis During Pregnancy
Matthew Wright¹, Dana Goin², Mette Kiel Smed³, Nicholas Jewell⁴, J Lee Nelson⁵, Merete Hetland⁶ and Damini Jawaheer⁷, ¹Children's Hospital Oakland Research Institute/Northwestern University, Chicago, ²UCSF, San Francisco, CA, ³Juliane Marie Centret, Copenhagen, Denmark, ⁴UC Berkeley, Berkeley, CA, ⁵University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, ⁶Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ⁷Children's Hospital Oakland Research Institute/Northwestern University, Chicago, IL
Background/Purpose: Pregnancy can induce a natural improvement of rheumatoid arthritis (RA) in 50-75% of women with the disease, while others may worsen or remain unchanged.…
Abstract Number: 0938 • ACR Convergence 2024
Group 2 Innate Lymphoid Cells Promote T Cell Activation and Development of Autoimmune Arthritis
Agnieszka Lastowska¹, Anders Nguyen², Miriam Bollmann² and Mattias Svensson³, ¹University of Gothenburg, Goteborg, Sweden, ²University of Gothenburg, Göteborg, Sweden, ³University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Innate Lymphoid Cells (ILCs) are the innate counterparts to T cells and can be divided into three functionally distinct subpopulations: Group 1 (ILC1), Group…
Abstract Number: 0990 • ACR Convergence 2024
Predictors of Adverse Events and Complications in Cirrhotic Patients with Rheumatoid Arthritis: A Nationwide Analysis
Nidaa Rasheed¹, Humzah Iqbal² and Candice Reyes³, ¹UCSF Fresno, Fresno, CA, ²UCSF FRESNO, FRESNO, ³VACCHCS, Fresno, CA
Background/Purpose: Cirrhosis is associated with a host of complications such as coagulopathy, renal impairment, esophageal varices, peritonitis, and increased mortality. Rheumatoid arthritis (RA) is a…
Abstract Number: 1042 • ACR Convergence 2024
Identifying Patient Priorities for Patient-Reported Outcome Measures in Rheumatoid Arthritis: A Modified Delphi Consensus Study
Racheal Githumbi¹, Steven Katz², Ania Kania-Richmond¹, Kim Giroux³, Yvonne Wallace³, Cheryl Barnabe¹, Glen Hazlewood¹, C. Allyson Jones², Amanda Steiman⁴, Anshula Ambasta¹, Diane Lacaille⁵, Elaine Yacyshyn², Jessica Widdifield⁶, Natasha Gakhal⁷, Tyler Williamson¹ and Claire Barber¹, ¹University of Calgary, Calgary, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³Patient Partner, Calgary, AB, Canada, ⁴Sinai Health System, Toronto, ON, Canada, ⁵Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ⁶Sunnybrook Research Institute / ICES / UofT Institute of Health Policy, Management & Evaluation, Toronto, ON, Canada, ⁷Women's College Hospital, Toronto, ON, Canada
Background/Purpose: Patient-reported outcome measures (PROMs) are essential tools for prioritizing patient-centric care and enhancing health system-performance measurement in rheumatology. Effective use of PROMs collected in…
Abstract Number: 1249 • ACR Convergence 2024
Patient-Reported Outcomes in Inflammatory Arthritis: A Four-Year Retrospective Analysis via the PatientSpot Research Registry
Shilpa Venkatachalam¹, Kelly Gavigan², Erik Stone³, Angela Degrassi², Laura Stradford⁴, David Curtis², Esteban Rivera⁵ and Jeffrey Curtis⁶, ¹Global Healthy Living Foundation, New York, NY, ²Global Healthy Living Foundation, Upper Nyack, NY, ³Global Healthy Living Foundation, Upper Nyack, ⁴Global Healthy Living Foundation, Nyack, NY, ⁵Global Healthy Living Foundation, Long Island City, NY, ⁶University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Understanding the impact of inflammatory arthritis from patients’ perspectives through patient-reported outcomes (PROs) data can provide valuable insights into outcomes prioritized by those living…
Abstract Number: 1338 • ACR Convergence 2024
Health Care Utilization and Cost of Herpes Zoster Infection in Patients with Rheumatoid Arthritis, a Retrospective Cohort Study
Mohammad Movahedi¹, Angela Cesta², Xiuying Li², Mark Tatangelo³ and Claire Bombardier³, and OBRI investigators, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²UHN, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) have approximately a twofold increased risk of developing herpes zoster (HZ) compared to the general population. This elevated risk is attributed…
Abstract Number: 1354 • ACR Convergence 2024
The Association of Genetic Variation in PTPN22 and Rheumatoid Arthritis Disease Activity
Thomas Riley¹, Austin Wheeler², Bryant England², grant Cannon³, Sauer brian⁴, Gary Kunkel⁵, Katherine Wysham⁶, Beth Wallace⁷, Rachel Elam⁸, Paul Monach⁹, Andreas Reimold¹⁰, Gail Kerr¹¹, Isaac Smith¹², John Richards¹³, Iris Lee¹⁴, Rui Xiao¹⁵, Scott Damrauer¹⁵, Michael George¹⁵, Ted Mikuls² and Joshua Baker¹⁵, ¹Hopsital of the University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁴Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁷Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁸Augusta University, Evans, GA, ⁹VA Boston Healthcare System, Boston, MA, ¹⁰Dallas VA Medical Center, Dallas, TX, ¹¹Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹²Duke University Hospital, Durham, NC, ¹³Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹⁴Washington University in St Louis, Saint Louis, MO, ¹⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: PTPN22 R620W is a common genetic variation that is a known risk factor for the development of autoimmune disease, including rheumatoid arthritis (RA). This…
Abstract Number: 1370 • ACR Convergence 2024
Upadacitinib vs TNFi and Other JAKi Treatment Outcomes in Australian Rheumatoid Arthritis Patients: Descriptive Comparison of Persistence and Effectiveness Using the OPAL Dataset
Sabina Ciciriello¹, Peter Youssef², Talib Tahir³, Tegan Smith⁴, Catherine O'Sullivan⁴, Joanna Leadbetter⁵, Belinda Butcher⁵, Miriam Calao⁶, Nicole Walsh⁶ and Geoffrey Littlejohn⁷, ¹The University of Melbourne, Melbourne, Victoria, Australia, ²Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia, ³Coburg Rheumatology Service, Coburg, Victoria, Australia, ⁴OPAL Rheumatology Ltd, Geelong, Victoria, Australia, ⁵WriteSource Medical Pty Ltd, Lane Cove, New South Wales, Australia, ⁶AbbVie Pty Ltd, Mascot, New South Wales, Australia, ⁷Monash University, Clayton, Victoria, Australia
Background/Purpose: To descriptively compare treatment patterns, persistence and effectiveness of upadacitinib (UPA), other JAK inhibitors (JAKi) and tumour necrosis factor inhibitors (TNFi) in rheumatoid arthritis…
Abstract Number: 1387 • ACR Convergence 2024
Olokizumab Effect on Chronic Pain in Rheumatoid Arthritis: Results of the Observational Study
Andrey Karateev¹, Sofia Kuzkina², Galym Togizbayev³, Elena Polishuk¹, Ekaterina Filatova¹, Vera Amirdzhanova¹, Victoria Khlaboshchina¹, Natalia Lapkina⁴, Andrey Baranov⁴ and Alexander Lila⁵, ¹V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ²R-Pharm, Moscow, Russia, ³Kazakh National Medical University named after Asfendiyarov S, Almaty, Kazakhstan, ⁴Yaroslavl State Medical University, Yaroslavl, Russia, ⁵Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation, Moscow, Russia
Background/Purpose: To evaluate efficacy and safety of olokizumab (interleukin-6 inhibitor) in RA patients with special attention to chronic pain and a signs of central sensitization.Methods:…
Abstract Number: 1405 • ACR Convergence 2024
Perceived Healthcare Discrimination Among Individuals with Musculoskeletal Conditions: A Retrospective Cross-Sectional Analysis
Titilayo Adeniran¹, Bertilia Trieu², Sandra Goldsmith¹ and Laura Robbins¹, ¹Hospital for Special Surgery (HSS), New York, NY, ²Hospital for Special Surgery, New York, NY
Background/Purpose: Musculoskeletal conditions, including osteoarthritis (OA), osteoporosis (OP), rheumatoid arthritis (RA), and chronic pain, significantly burden individuals' health and well-being. These conditions often lead to…
Abstract Number: 1682 • ACR Convergence 2024
Early Development of Ocadusertib, a Selective Receptor-Interacting Serine/Threonine-Protein Kinase 1 Inhibitor
Eric Hanson¹, Daniel Dairaghi¹, Andrew C. Vendel¹, Jonathan Sims¹, Yasushi Takita¹, Lucy Yan², Andrew Chow², Simon Shaw² and esteban S. Masuda², ¹Eli Lilly and Company, Indianapolis, IN, ²Rigel Pharmaceuticals, San Francisco
Background/Purpose: Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors are under investigation in chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Ocadusertib (LY3871801;…
Abstract Number: 1846 • ACR Convergence 2024
Citrullinated Vimentin-reactive Immune-regulatory CD4+CD39+TIGIThi T Cells Expand During Drug Free Remission in HLA-DR Shared-epitope+ ACPA+ Rheumatoid Arthritis
Amy Anderson¹, Henrique de Paula Lemos¹, Hendrik Nel², Sofia Sorbet Santiago¹, Fiona Rayner³, Abbie Degnan¹, Imogen Wilson¹, Julie Diboll¹, Jasmine Sim¹, Andrew Melville⁴, Stefan Siebert⁴, Iain McInnes⁵, Carl Goodyear⁴, Catharien Hilkens¹, Andrew Filer⁶, Karim Raza⁶, Christopher Buckley⁷, Hugh Reid⁸, Kenneth Baker¹, Arthur Pratt³, Jamie Rossjohn⁸, Ranjeny Thomas⁹ and John Isaacs¹, ¹Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ²Frazer Institute, The University of Queensland, Translational Research Institute, Brisbane, Australia, ³Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, ⁴School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁵University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ⁶Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, ⁷Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ⁸Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Victoria, Australia, ⁹University of Queensland, Brisbane, Australia
Background/Purpose: There is a need for immunotherapy that sustains symptom remission without ongoing need for disease modifying drugs (DMARDs). In a phase 1b trial of…
Abstract Number: 1905 • ACR Convergence 2024
Combining Three Peripheral Biomarkers to Stratify Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk
Bryant England¹, Austin Wheeler¹, Brent Luedders¹, Michael Duryee¹, Halie Frideres², Katherine Wysham³, grant Cannon⁴, Gary Kunkel⁵, Dana Ascherman⁶, Paul Monach⁷, Gail Kerr⁸, Andreas Reimold⁹, Joshua Baker¹⁰, Geoffrey Thiele¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC Department of Rheumatology, Omaha, NE, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁷VA Boston Healthcare System, Boston, MA, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁹Dallas VA Medical Center, Dallas, TX, ¹⁰Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA
Background/Purpose: Several peripheral biomarkers for RA-associated interstitial lung disease (RA-ILD) have been evaluated to enhance early RA-ILD identification. The MUC5B rs35705950 promoter variant, matrix metalloproteinase-7…
Abstract Number: 2121 • ACR Convergence 2024
Increased Fracture Rates in Patients Continuing Methotrexate After Methotrexate-associated Lower Limb Insufficiency Fractures: A Retrospective Follow-up Study
Roba Ghossan¹, OLIVIER FOGEL², Christian Roux¹ and Karine Briot¹, ¹COCHIN HOSPITAL, PARIS, France, ²AP-HP, Paris, France
Background/Purpose: Spontaneous lower limb insufficiency fractures (LLIF) described under prolonged exposure to low-dose methotrexate are often bilateral, multiple, and recurrent. They share a common pathognomonic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].